Trial Profile

Management of Parkinson's Disease Psychosis in Actual Practice (The INSYTE Study)

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimavanserin (Primary) ; Aripiprazole; Clozapine; Olanzapine; Quetiapine
Indications Parkinson's disease
Focus Adverse reactions; Therapeutic Use
Sponsors Acadia Pharmaceuticals

Most Recent Events

30 Jul 2021 Status changed from recruiting to discontinued.
29 Nov 2018 New trial record
14 Nov 2018 Interim results (n=90) presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com